scholarly journals The Oxidative Status and Na +/K + -ATPase Activity in Obsessive-Compulsive Disorder: A Case Control Study

2021 ◽  
Author(s):  
Amir Hossein Mohammadi ◽  
Ebrahim Balandeh ◽  
Jila Hasani ◽  
Mohammad Karimian ◽  
Morteza Pourfarzam ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Vitamin A ◽  
Atpase Activity ◽  
Obsessive Compulsive Disorder ◽  
Serum Vitamin ◽  
Reversed Phase ◽  
Lower Activity ◽  
Obsessive Compulsive ◽  
Compulsive Disorder ◽  
Rbc Membrane

Abstract Background: Oxidative stress is involved in pathogenesis of some psychiatric disorders. To examine the role of oxidative stress in the etiopathogenesis of obsessive-compulsive disorder (OCD), we aimed to determine oxidative stress indices, including MDA levels in serum and red blood cells (RBC) membrane, total antioxidant capacity (TAC), serum glutathione (GSH) levels, serum antioxidant vitamins (A and E) and Na+/K+-ATPase activity in patients with the mentioned disorder vs. healthy controls.Method: 39 OCD patients diagnosed based on Diagnostic and Statistical Manual of Mental Disorders (DSM-V), and 39 volunteers’ healthy subjects were included in this study. MDA levels in serum and RBC membrane were measured using fluorimetric method. Serum TAC level, serum GSH level and Na+/K+-ATPase activity were also measured using spectrophotometric methods. Serum levels of vitamins were calculated by Reversed-phase high-performance liquid chromatography (RP-HPLC).Result: There was a significantly higher MDA level in serum (p<0.0001) and RBC membrane (p=0.002) of OCD patients compared with those in controls. A significant reduction in vitamin A (p=0.024) and vitamin E (p=0.001) levels was found in OCD patients vs. controls. There was significantly lower activity of erythrocyte membrane Na+-K+ ATPase in RBC membrane of OCD patients vs. controls (p<0.0001).Conclusion: Our findings indicate significantly higher levels MDA in both serum and RBC membrane, lower levels of serum vitamin A and E, and lower activity of membrane Na+-K+ ATPase in OCD patients compared to controls. These suggest an imbalance between oxidant and antioxidant factors in OCD patients that might play a fundamental role in the etiopathogenesis of OCD.

A study of oxidative stress biomarkers in obsessive compulsive disorder

2017 ◽  
Vol 15 ◽  
pp. 52-56 ◽  
Author(s):  
Abhijeet Shrivastava ◽  
Sujita Kumar Kar ◽  
Eesha Sharma ◽  
Abbas Ali Mahdi ◽  
Pronob Kumar Dalal
Keyword(s):  
Oxidative Stress ◽  
Obsessive Compulsive Disorder ◽  
Obsessive Compulsive ◽  
Oxidative Stress Biomarkers ◽  
Compulsive Disorder ◽  
Stress Biomarkers

scholarly journals Study of oxidative stress in obsessive compulsive disorder in response to treatment with Fluoxetine

2009 ◽  
Vol 24 (2) ◽  
pp. 194-197 ◽  
Author(s):  
Sutirtha Chakraborty ◽  
Anindya Dasgupta ◽  
Harendra Nath Das ◽  
Om Prakash Singh ◽  
Asok Kumar Mandal ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Obsessive Compulsive Disorder ◽  
Response To Treatment ◽  
Obsessive Compulsive ◽  
Compulsive Disorder

scholarly journals The Role of Antioxidants in the Management of Obsessive-Compulsive Disorder

2021 ◽  
Vol 2021 ◽  
pp. 1-15
Author(s):  
Fatemeh Baratzadeh ◽  
Sepideh Elyasi ◽  
Amir Hooshang Mohammadpour ◽  
Sofia Salari ◽  
Amirhossein Sahebkar
Keyword(s):  
Oxidative Stress ◽  
Obsessive Compulsive Disorder ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Human Studies ◽  
Large Sample Size ◽  
Antioxidant Treatment ◽  
Obsessive Compulsive ◽  
Compulsive Disorder

Obsessive-compulsive disorder (OCD) is a chronic neuropsychiatric disorder that has a significant effect on the quality of life. The most effective treatment for OCD is the combination of selective serotonin reuptake inhibitors (SSRI) with cognitive behavior therapy (CBT). However, several adverse effects have been linked with this usual pharmacotherapy, and it is unsuccessful in many patients. The exact pathophysiology of OCD is not completely known, though the role of oxidative stress in its pathogenesis has been proposed recently. This review presents an overview of animal and human studies of antioxidant treatment for OCD. The use of antioxidants against oxidative stress is a novel treatment for several neurodegenerative and neuropsychiatric disorders. Among antioxidants, NAC was one of the most studied drugs on OCD, and it showed a significant improvement in OCD symptoms. Thus, antioxidants could be promising as an adjuvant treatment for OCD. However, a limited number of human studies are conducted on these agents, and for better judgment, human studies with a large sample size are necessary.

Serum Vitamins and Homocysteine Levels in Obsessive-Compulsive Disorder: A Systematic Review and Meta-Analysis

2021 ◽  
pp. 1-14
Author(s):  
Ebrahim Balandeh ◽  
Mohammad Karimian ◽  
Mohaddeseh Behjati ◽  
Amir Hossein Mohammadi
Keyword(s):  
Vitamin B12 ◽  
Obsessive Compulsive Disorder ◽  
Fixed Effects ◽  
Meta Analysis ◽  
Serum Vitamin ◽  
Fixed Effects Model ◽  
Obsessive Compulsive ◽  
Compulsive Disorder ◽  
Standard Mean Difference ◽  
Vitamin B9

Vitamin and homocysteine (Hcy) alternations have been associated with psychiatric disorders. The aim of this meta-analysis was to assess the association of serum vitamin and Hcy levels with obsessive-compulsive disorder (OCD). Following PRISMA protocol, we used the databases including Scopus, PubMed, Google Scholar, and Web of Science with no time restriction. Data were pooled using a random-effects model and/or fixed-effects model to estimate the standard mean difference (SMD) for evaluation of the strength of association analyses. Our data showed a significant reduction in vitamin B12 (SMD = −0.58, 95% CI = −1.08 to −0.08, p = 0.02, I2 = 65%; pheterogeneity = 0.06), vitamin E (SMD = −0.89, 95% CI = −1.23 to −0.56, p < 0.00001, I2 = 23%; pheterogeneity = 0.26), and vitamin C (SMD = −1.40, 95% CI = −2.44 to −0.36, p = 0.008, I2 = 92%; pheterogeneity < 0.0001) in OCD patients. In addition, the findings showed significantly higher levels of Hcy (SMD = 1.11, 95% CI = [0.48, 1.75], p = 0.0006, I2 = 73%; ph = 0.02) in patients compared to controls. Also, our data showed that vitamin B9 and D levels are not associated with OCD (vitamin B9: SMD = −0.23, 95% CI = −1.01 to 0.55, p = 0.56, I2 = 88%; pheterogeneity < 0.0001; vitamin D: SMD = −0.63, 95% CI = −1.41 to 0.15, p = 0.11, I2 = 88%; pheterogeneity = 0.0002). Our findings support significant impacts of Hcy and vitamin B12, E, and C levels in OCD pathogenesis. This will be important for prevention and treatment of OCD. However, further studies are recommended to elucidate more accurate conclusions.

scholarly journals Lithium: a potential therapeutic strategy in obsessive–compulsive disorder by targeting the canonical WNT/β pathway

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Alexandre Vallée ◽  
Jean-Noël Vallée ◽  
Yves Lecarpentier
Keyword(s):  
Oxidative Stress ◽  
Obsessive Compulsive Disorder ◽  
Therapeutic Strategy ◽  
Behavioral Therapy ◽  
First Line ◽  
Obsessive Compulsive ◽  
Compulsive Disorder ◽  
First Line Therapy ◽  
New Treatment ◽  
Gsk 3Β

AbstractObsessive–compulsive disorder (OCD) is a neuropsychiatric disorder characterized b–y recurrent and distinctive obsessions and/or compulsions. The etiologies remain unclear. Recent findings have shown that oxidative stress, inflammation, and the glutamatergic pathway play key roles in the causes of OCD. However, first-line therapies include cognitive–behavioral therapy but only 40% of the patients respond to this first-line therapy. Research for a new treatment is mandatory. This review focuses on the potential effects of lithium, as a potential therapeutic strategy, on OCD and some of the presumed mechanisms by which lithium provides its benefit properties. Lithium medication downregulates GSK-3β, the main inhibitor of the WNT/β-catenin pathway. The activation of the WNT/β-catenin could be associated with the control of oxidative stress, inflammation, and glutamatergic pathway. Future prospective clinical trials could focus on lithium and its different and multiple interactions in OCD.

Sign in / Sign up

Export Citation Format

Share Document